June 12, 2026
A personalized mRNA cancer vaccine has demonstrated a 90% tumor response rate in a landmark Phase 2 clinical trial, marking one of the most significant advances in oncology in decades. The vaccine, developed through a collaboration between Moderna and the Memorial Sloan Kettering Cancer Center, trains the immune system to recognize and attack mutations unique to each patient’s tumor — a truly individualized approach to cancer treatment.
The trial enrolled 162 patients across eight countries, all diagnosed with advanced melanoma that had spread to lymph nodes. Each participant received a custom-built vaccine within 45 days of their surgical resection, designed using whole-genome sequencing of their individual tumor. The results, published this week in The New England Journal of Medicine, showed that 146 of 162 patients — or exactly 90.1% — exhibited measurable tumor regression or complete pathological response at the 18-month mark.
What sets this approach apart from conventional immunotherapy is its precision. Traditional cancer vaccines target common antigens shared across many patients, which often limits their effectiveness as tumors evolve escape mechanisms. The mRNA platform sidesteps this by encoding up to 34 neoantigens identified specifically in the patient’s own tumor biopsy. When injected, the vaccine prompts the immune system to launch a targeted T-cell response against cells bearing those markers, leaving healthy tissue largely untouched.
Side effects were manageable across the cohort, with fatigue, fever, and localized injection-site reactions reported in the majority of patients — similar to those seen with existing mRNA COVID-19 vaccines. No patients discontinued treatment due to immune-related adverse events, a concern that had shadowed earlier personalized immunotherapy trials.
Dr. Priya Mehta, the trial’s lead oncologist and director of translational immunology at MSKCC, called the results “a paradigm shift in how we conceptualize cancer treatment.” She noted that the 90% response rate held even in patients whose tumors had previously resisted checkpoint inhibitor therapy — a population with historically poor prognoses. “These are patients who had exhausted standard options,” she said. “We are seeing durable responses in a cohort that, six years ago, we would have sent to hospice care.”
The FDA has granted the vaccine Breakthrough Therapy Designation, expediting the regulatory review process. A Phase 3 trial, expected to enroll more than 1,200 patients across 14 countries, is scheduled to begin in September. If the results replicate at that scale, the treatment could be available to the public by late 2027 — an unusually fast timeline for an oncology drug, reflecting both the gravity of the unmet need and the regulatory appetite for acceleration.
The broader implications for cancer medicine are considerable. Researchers are already exploring whether the mRNA platform could be adapted to pancreatic, lung, and colorectal cancers — three of the deadliest and most treatment-resistant tumor types. The personalized manufacturing process, which currently takes 35 to 45 days per patient, is also being streamlined. Moderna has committed to reducing turnaround time to under three weeks by 2027, making the approach feasible for a broader patient population.
At a cost currently exceeding $120,000 per patient — a figure that includes genome sequencing, antigen selection, and manufacturing — access remains a profound concern. Advocacy groups have warned that without aggressive pricing negotiations or public subsidy, the therapy risks becoming yet another breakthrough available only to the wealthy. The Centers for Medicare and Medicaid Services has opened a pricing review inquiry, with a preliminary assessment expected before year-end.
For oncologists and patients alike, the trial represents a turning point in the long effort to make cancer a manageable rather than fatal diagnosis. “Five years ago, I would not have used the word ‘cure’ in the same sentence as metastatic melanoma,” said Dr. Mehta. “I am now beginning to use it.”